Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bronchodilators

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44350   clinical trials with a EudraCT protocol, of which   7377   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    155 result(s) found for: Bronchodilators. Displaying page 4 of 8.
    « Previous 1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2005-001122-87 Sponsor Protocol Number: FFA20003 Start Date*: 2005-09-19
    Sponsor Name:GlaxoSmithKline Research and Development
    Full Title: A Randomized Double-Blind Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder 200mcg, 400mcg, 600mcg and 800mcg Administered On...
    Medical condition: Patients with persistent bronchial asthma symptomatic on moderate dose inhaled corticosteroid therapy.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001248-30 Sponsor Protocol Number: XRP1526B/3031 Ciclesidone Start Date*: 2006-06-16
    Sponsor Name:Sanofi-Aventis U.S. Inc.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 μg administered either in a once-...
    Medical condition: Asthma is a chronic inflammatory disease of the airways characterized by airway hyperresponsiveness, acute and chronic bronchoconstriction, airway edema, and mucus plugging. The inflammatory compon...
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004208-39 Sponsor Protocol Number: BAYq3939/15625 Start Date*: 2013-01-21
    Sponsor Name:Bayer HealthCare AG
    Full Title: Randomized, double-blind, placebo-controlled, multicEnter Study comParing CIprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus p...
    Medical condition: bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10006445 Bronchiectasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) IT (Completed) DK (Completed) FR (Completed) LV (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2004-000404-40 Sponsor Protocol Number: BAY 12-8039/11229 Start Date*: 2004-09-06
    Sponsor Name:Bayer plc
    Full Title: A double-blind, randomised, placebo controlled study to investigate chronic intermittent “pulse” therapy of moxifloxacin as a prevention of acute exacerbation in out-patients with chronic bronchitis.
    Medical condition: Chronic bronchitis
    Disease: Version SOC Term Classification Code Term Level
    10008841
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003570-77 Sponsor Protocol Number: SB010/04/2012 Start Date*: 2012-12-04
    Sponsor Name:sterna biologicals GmbH & Co. KG
    Full Title: Clinical study to investigate safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple doses of the human GATA-3-specific DNAzyme solution SB010 in patients with mild aller...
    Medical condition: The trial will be conducted in 38 male patients with mild allergic asthma and documented or known biphasic reaction to allergen challenge (AC).
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005048-17 Sponsor Protocol Number: VRP080415 Start Date*: 2009-01-27
    Sponsor Name:Verona Pharma Plc
    Full Title: A Combined Clinical Phase I/IIa Study of the Safety and Efficacy of Nebulised RPL554 in Healthy Subjects, Allergic Asthmatics, and Allergic Rhinitics
    Medical condition: Allergic Asthma and Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001705 Allergic asthma LLT
    9.1 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-005819-10 Sponsor Protocol Number: KKS-95 Start Date*: 2007-12-07
    Sponsor Name:Philipps-University Marburg
    Full Title: Influence of tiotropium bromide (Spiriva ®) plus salbutamol versus salbutamol on the mucin secretion and sputum properties in subjects with a COPD exacerbation -TIBROMUC-
    Medical condition: Anticholinergic bronchodilators, such as ipratropium bromide, may be used in combination with beta adrenergic agonists as SAlbutamol to produce bronchodilation in excess of that achieved by either ...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10010952 COPD LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001891-19 Sponsor Protocol Number: B2F104302 Start Date*: 2006-09-28
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A multi-centre, randomised, dose-ascending, double-blind, placebo-controlled, four-way incomplete block crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokine...
    Medical condition: Asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003449-17 Sponsor Protocol Number: MC/PR/15009/001/11 Start Date*: 2012-05-31
    Sponsor Name:CHIESI
    Full Title: A 12-week, multicenter, randomized, double-blind, double-dummy, 2-arm parallel group study comparing the efficacy and safety of Foster NEXThaler (beclomethasone dipropionate 100 µg plus formotero...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004527-42 Sponsor Protocol Number: W10-664 Start Date*: 2015-02-03
    Sponsor Name:Abbott Laboratories LLC
    Full Title: A Prospective, Multicenter, Open-label, Non-comparative Study of Safety and Efficacy of Synagis® in Children at High Risk of Severe Respiratory Syncytial Virus Infection in the Russian Federation.
    Medical condition: Severe Respiratory Syncytial Virus Infection (RSV)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-002337-20 Sponsor Protocol Number: 2412325-2 Start Date*: 2006-09-06
    Sponsor Name:Erasmus Medical Centre Rotterdam
    Full Title: Efficacy of peripherally targeted inhaled rhDNase for persistent obstructive asthma in childhood
    Medical condition: Asthma is a chronic inflammatory disorder in which many cells play a role, in particular mast cells, eosinophils and T lymphocytes. In susceptible individuals this inflammation causes recurrent epi...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003553 Asthma LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001124-36 Sponsor Protocol Number: FFA20002 Start Date*: 2005-09-19
    Sponsor Name:GlaxoSmithKline Research and Development
    Full Title: A Randomized Double-Blind Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder 100mcg, 200mcg, 300mcg and 400mcg Administered On...
    Medical condition: Persistent asthma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) SK (Completed) LV (Prematurely Ended) EE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000522-46 Sponsor Protocol Number: CCD-0606-PR-0019 Start Date*: 2007-07-11
    Sponsor Name:Chiesi Farmaceutici S.p.A
    Full Title: A 12-WEEK, MULTICENTER, MULTINATIONAL, RANDOMISED, DOUBLE BLIND, DOUBLE-DUMMY (OPEN LABEL FOR THE SPACER GROUP), 3-ARM PARALLEL GROUP STUDY COMPARING THE EFFICACY AND THE SAFETY OF CHF 1535 HFA pMD...
    Medical condition: Moderate to severe asthma in adolescent patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) PL (Ongoing) SK (Completed)
    Trial results: View results
    EudraCT Number: 2015-004883-12 Sponsor Protocol Number: ADA109057 Start Date*: 2016-12-08
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in ...
    Medical condition: Asthma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-003279-23 Sponsor Protocol Number: MOMEL27 Start Date*: 2020-01-13
    Sponsor Name:Radboudumc
    Full Title: Phase 2 Study testing the COmbination of Vemurafenib With Cobimetinib in BRAF V600 mutated Melanoma Patients to Normalize LDH and Optimize immunotherapY with Nivolumab and Ipilimumab (COWBOY)
    Medical condition: Stage IV or unresectable stage III, BRAFV600E/K mutation positive melanoma, naïve for BRAF/MEK, PD-1/PD-L1 or CTLA-4 targeting therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005228-18 Sponsor Protocol Number: FFA106783 Start Date*: 2007-01-12
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of GW685698X 200mcg Twice Daily, GW685698X 200mcg and 400mcg Once Daily in the ...
    Medical condition: Persistent asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005534-20 Sponsor Protocol Number: 05102006 Start Date*: 2008-01-24
    Sponsor Name:Imperial College London
    Full Title: Effect of Erdosteine on inflammatory and oxidative biomarkers in sputum and exhaled breath in patients with COPD
    Medical condition: Chronic obstructive pulmonary disease (COPD) of different severity
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003264-65 Sponsor Protocol Number: sm2006msd01 Start Date*: 2007-01-22
    Sponsor Name:University of Dundee
    Full Title: A Proof-of-Concept Study to evaluate the benefit from add-on therapy with montelukast versus salmeterol in children with asthma carrying the Arg/Arg-16 beta2-receptor genotype
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003553 Asthma LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000130-39 Sponsor Protocol Number: NEO014/FP/pMDI/paed Start Date*: 2007-02-08
    Sponsor Name:Neolab Ltd
    Full Title: A PHASE III, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED CROSSOVER STUDY TO COMPARE THE SYSTEMIC EFFECTS OF INHALED FLUTICASONE PROPIONATE HFA MDI 200g PER DAY VERSUS THE REFERENCE ...
    Medical condition: Mild asthma in pre-pubertal children.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019989-91 Sponsor Protocol Number: LPA114387 Start Date*: 2010-11-25
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Treatment, Three 6-Week Period Cross-Over, Multi-Center Exploratory Study to Evaluate the Effect of Adding GSK2190915 300mg Table...
    Medical condition: Asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 18 12:26:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA